RedHill Biopharma Ltd. (RDHL)
NASDAQ: RDHL · IEX Real-Time Price · USD
0.364
+0.002 (0.44%)
Jul 22, 2024, 10:15 AM EDT - Market open
RedHill Biopharma Employees
RedHill Biopharma had 53 employees as of December 31, 2023. The number of employees decreased by 60 or -53.10% compared to the previous year.
Employees
53
Change (1Y)
-60
Growth (1Y)
-53.10%
Revenue / Employee
$123,208
Profits / Employee
$451,245
Market Cap
11.59M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Check-Cap | 85 |
Senti Biosciences | 48 |
Calidi Biotherapeutics | 41 |
Vaccinex | 40 |
Lumos Pharma | 33 |
Imunon | 33 |
BioRestorative Therapies | 11 |
Monopar Therapeutics | 10 |
RDHL News
- 3 hours ago - RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien - PRNewsWire
- 13 days ago - RedHill Biopharma Terminates License Agreement for Aemcolo® - PRNewsWire
- 7 weeks ago - RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040 - PRNewsWire
- 2 months ago - RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035 - PRNewsWire
- 3 months ago - RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study - PRNewsWire
- 3 months ago - RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights - PRNewsWire
- 3 months ago - RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price - PRNewsWire
- 4 months ago - RedHill Announces New USPTO Patent Covering Talicia® Through 2034 - PRNewsWire